Prognosis

St. Croix Hospice Awarded for Exceptional Marketing Campaign

Retrieved on: 
Wednesday, March 20, 2024
Assistant, Hospice, Patient, News, Communication, Ageing, Marketing, Prognosis, Medicare, Nursing

Recognized by Aging Media's Aspect Awards for the third consecutive year, St. Croix Hospice continues to fortify their position as leaders within the hospice community.

Key Points: 
  • Recognized by Aging Media's Aspect Awards for the third consecutive year, St. Croix Hospice continues to fortify their position as leaders within the hospice community.
  • This year's recognition applauded the agency's successful multimedia campaign to raise awareness of end-of-life care during Hospice Month 2023.
  • "St. Croix Hospice is passionate about leveraging strategic marketing tactics that raise awareness of the hospice benefit, consequently increasing communities' access to a compassionate end-of-life experience," said St. Croix Hospice's Assistant Vice President of Marketing and Communications, Bronwyn Pope.
  • Taking an integrated approach to hospice care, the expert team at St. Croix Hospice provides physical, emotional and spiritual support to more than 4,400 patients daily.

Caris Life Sciences to Showcase Research at 2024 SGO Annual Meeting on Women's Cancer

Retrieved on: 
Wednesday, March 13, 2024
Diagnosis, PR, UCS, NCI, Ovarian cancer, Promise, OSCC, Survival, EEC, Exome sequencing, Glomus tumor, TMB, Patient, Neoplasm, NGS, Biomarker, Research, DNA, RNA, Cancer, AI, SGO, Carcinosarcoma, MD, Endometrial cancer, Medicine, Abstract, POA, Prognosis, Poster, ETS, Medical imaging

IRVING, Texas, March 13, 2024 /PRNewswire/ -- Caris Life Sciences®(Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition using molecular science and AI, announced today that the company and collaborators within the Caris Precision Oncology Alliance™ (POA) will collectively present three studies across multiple gynecological tumor types at the 2024 SGO Annual Meeting on Women's Cancer, March 16-18, 2024, in San Diego. The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene, to enable novel insights into cancer that could have profound effects on a patient's diagnosis, prognosis, care plan and response to treatment.

Key Points: 
  • The findings demonstrate the power of Caris' comprehensive multi-modal database, generated by examining every gene
    "We are proud to return and present an array of precision oncology research at this year's SGO Annual Meeting.
  • The Proactive Molecular Risk Classifier for Endometrial Cancer (ProMisE) criteria classify four molecular subtypes of endometrial tumors (ET).
  • Poster and abstract summaries highlighting the Caris research presented at SGO 2024 will be available onsite at Caris' booth (#601).
  • The POA includes 91 cancer centers, academic institutions, research consortia and healthcare systems, including 43 NCI-designated cancer centers, collaborating to advance precision oncology and biomarker-driven research.

Zenith Epigenetics Proudly Supports Rare Disease Day

Retrieved on: 
Thursday, February 29, 2024
Rare disease, Head, NUT, Aggression, Neck, Quality of life, Health, Zenith, Cell, Prevalence, Prognosis, Patient, Nervous tissue, Clinical trial, NUT carcinoma, Disease, Survival, Sympathetic nervous system, Diagnosis, Metastasis, BET, Carcinoma, Cancer, Pharmaceutical industry

ZEN-3694 Expands Development to Include Multiple Rare Oncology Indications

Key Points: 
  • Calgary, Alberta--(Newsfile Corp. - February 29, 2024) - Zenith Epigenetics Ltd. ("Zenith" or the "Company") announces its support of Rare Disease Day by highlighting our expanded development efforts of BET inhibitor ZEN-3694 for rare oncology diseases.
  • Rare Disease Day takes place every year on the last day of February, with this leap year day being the rarest of all Rare Disease Days.
  • This event is a global movement to promote equity in healthcare, and access to diagnosis and therapies for individuals living with rare diseases.
  • We are very pleased that NUT carcinoma patients receiving ZEN-3694 in clinical trial and compassionate use settings have benefitted from our drug," said Donald McCaffrey, CEO of Zenith Epigenetics.

Abell Pest Control Sheds Light on Tick Surge

Retrieved on: 
Monday, March 11, 2024
Head, University, Pet, Social media, Tick, Research, DEET, Deer, Temperature, Lyme disease, Infection, Dog, NSF, Skin, Government, Risk, Notifiable disease, Climate, National Pest Management Association, Bacteria, Prognosis, Quality assurance, Water, Cat, Health policy, Survival, Knowledge, Diagnosis, Borrelia burgdorferi, Trust, University of Guelph, Student

Due to global warming, the recent abnormally warm winter has allowed ticks to move to new areas and lengthen their active season,” explained Aaron Soudant, Director of Quality Assurance at Abell Pest Control.

Key Points: 
  • Due to global warming, the recent abnormally warm winter has allowed ticks to move to new areas and lengthen their active season,” explained Aaron Soudant, Director of Quality Assurance at Abell Pest Control.
  • Abell Pest Control offers the following tips to avoid tick bites and minimize the risk of Lyme disease:
    Dress Appropriately: Wear long pants, and long sleeves and opt for light-colored clothing to make ticks easier to spot.
  • Abell Pest Control, a leader in pest control solutions, is dedicated to raising awareness about tick-borne illnesses and empowering communities with knowledge and resources for protection.
  • Celebrating 100 years of trust, Abell Pest Control has been safeguarding homes and businesses since 1924.

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

Retrieved on: 
Sunday, March 10, 2024
Psoriatic arthritis, ACR, Doctor of Philosophy, Adalimumab, Skin, American College, Webcast, Moonlake, HS, Patient, Psoriasis, VELA, MMSc, ARGO, MIRA, EDT, Physician, Inflammation, Safety, Prognosis, Clinical trial, Ankylosing spondylitis, TNF, IL-17A, MDA, American Academy, EMA, Medical college, FDA, Food, Steroid, Prevalence, AAD, Event, Joint, PASI, Hidradenitis suppurativa, PSA, PPP, Disease, Porokeratosis, Medicine, Pharmaceutical industry

In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.

Key Points: 
  • In addition, by week 24, over 80% and 60% of patients treated with sonelokimab achieved Psoriasis Area Severity Index (PASI) 90 and 100, respectively.
  • Treatment with sonelokimab resulted in unprecedented improvements in composite scores that reflect responses in different domains simultaneously.
  • In all composite scores, sonelokimab showed 16-29 percentage point differences to the reference adalimumab arm, comparatively higher to competitors using the same reference arm.
  • The discontinuation rate of the second part of ARGO remained low at 5%, in line with other sonelokimab trials.

Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, February 27, 2024
NSCLC, Leukemia, Research, AML, Pedal, QT interval, FTI, Mirati Therapeutics, Investment, Postcholecystectomy syndrome, Physician, Clinical trial, ID, HRAS, Mirati, Prognosis, Renal cell carcinoma, FLT3, Webcast, Patient, KURA, Disease, G&A, LDAC, HNSCC, Cancer, Pharmaceutical industry

ET –

Key Points: 
  • ET –
    SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported fourth quarter and full year 2023 financial results and provided a corporate update.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $32.5 million, compared to $22.7 million for the fourth quarter of 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $14.2 million, compared to $12.5 million for the fourth quarter of 2022.
  • ET / 1:30 p.m. PT today, February 27, 2024, to discuss the financial results for the fourth quarter and full year 2023 and to provide a corporate update.

Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Retrieved on: 
Monday, February 26, 2024
AML, Azacitidine, Menin, KMT2A, Safety, Prognosis, FLT3, Pharmacokinetics, Venetoclax, Patient, KURA, Kura, Acute myeloid leukemia, LDAC, Cancer, Pharmaceutical industry

SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patient has been dosed in KOMET-008, the Company’s Phase 1 trial of its menin inhibitor ziftomenib, in combination with gilteritinib, FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML).

Key Points: 
  • “Roughly half of patients with relapsed or refractory NPM1-mutant AML have co-occurring FLT3 mutations, and the prognosis for these patients is particularly poor,” said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology.
  • Trial participants will be enrolled in one of five dose escalation cohorts, including a cohort of NPM1-mutant AML patients with a documented FLT3 co-mutation, who will be treated in combination with the FLT3 inhibitor gilteritinib.
  • Kura is conducting a series of studies to evaluate ziftomenib in combination with current standards of care in earlier lines of therapy and across multiple patient populations.
  • Preclinical data for menin inhibitors in combination with multiple FLT3 inhibitors demonstrate strong synergistic effects compared to either single agent alone.

Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market Research Report 2024 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 7, 2024
Health, Oncology, Breast cancer, Incidence, Growth, Biomarker, Prognosis, Organization, Medical imaging

The "Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia-Pacific Next-Generation Breast Cancer Diagnostic and Screening Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering.
  • The anticipated growth in the next-generation breast cancer diagnostic and screening market is projected to be fueled by several factors.
  • With these dynamics in play, the APAC next-generation breast cancer diagnostic and screening market presents promising opportunities for improved breast cancer management and outcomes across the region.
  • Competitive Strategy: Key players in the APAC next-generation breast cancer diagnostic and screening market analyzed and profiled in the study involve players that offer next-generation breast cancer diagnostic and screening products and services.

 Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Retrieved on: 
Thursday, March 7, 2024
Research, Women, Clinical Trials, Biotechnology, Health, Consumer, Pharmaceutical, Science, Oncology, Cancer, Woman, Omics, Uterine serous carcinoma, Female, EOC, Risk, Safety, Biomarker, Prognosis, Endometrial cancer, DDR, USC, Patient, Fibroadenoma, Infection, Diagnosis, WEE1, Lymph, Fallopian tube cancer

The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.

Key Points: 
  • The expansion of this Phase 1 study, NCT05109975 , is to characterize the safety, tolerability, and initial signs of antitumor activity of Debio 0123 when administered as monotherapy.
  • Two out of the three expansion arms of the study will be using biomarkers to pre-select patients with different solid tumors while the third arm will be treating patients with recurrent serous endometrial carcinoma.
  • Maximizing efficacy, while preserving safety are key elements that Debiopharm is eager to assess throughout the clinical development of Debio 0123.
  • With the successful realization of these requirements, Debio 0123 could become the first choice WEE1 inhibitor.

QuidelOrtho Receives Health Canada Approval for Quidel® Triage® PLGF Test for Laboratory Use in Canada

Retrieved on: 
Wednesday, March 6, 2024
Data Management, Biotechnology, Baby, Maternity, Technology, Other Health, Health, Women, Health Technology, Medical Devices, Consumer, Clinical Trials, Pre-eclampsia, Eclampsia, Woman, Transfusion medicine, QuidelOrtho, Health Canada, Quality, Premature, Pregnancy, Risk, Diagnosis, Quality control, Safety, Prognosis, Biomarker, Lancet, Triage, Stillbirth, Guideline, HELLP, Placenta, Plasma, HELLP syndrome, Placentation, Medical device

QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, has received approval from Health Canada for its Triage PLGF test for laboratory use in Canada.
  • The Triage PLGF test is a fluorescence immunoassay to be used with the small footprint Triage MeterPro® Instrument for the quantitative determination of placental growth factor (“PLGF”) in maternal plasma specimens.
  • With the Triage PLGF test, clinicians can be positioned to better detect angiogenic imbalance and assess the risk for these complications.
  • The Triage PLGF test is available to customers in Canada for use with the Triage MeterPro instrument.